Letter to the Editor: "Docetaxel and its nanoformulations: how delivery strategies could impact the therapeutic outcome?"
Ther Deliv
.
2021 May;12(5):343-344.
doi: 10.4155/tde-2020-0120.
Epub 2021 Mar 29.
Authors
Mujtaba A Khan
1
,
Nisarg Joshi
1
,
Imran Ahmad
2
Affiliations
1
Medical Affairs & Clinical Development, Intas Pharmaceuticals Ltd., Sola, Ahmedabad, Gujarat 380054, India.
2
Jina Pharmaceuticals Inc., Libertyville, IL 60048, USA.
PMID:
33775104
DOI:
10.4155/tde-2020-0120
No abstract available
Keywords:
NDLS; docetaxel; nanoparticle; nanosomal docetaxel lipid suspension.
Publication types
Letter
Comment
MeSH terms
Antineoplastic Agents*
Docetaxel
Drug Carriers
Treatment Outcome
Substances
Antineoplastic Agents
Drug Carriers
Docetaxel